← Back

ChemoMetec A/S

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5, a versatile cell analyzer. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.

Price · split & dividend adjusted
News & notes moving 0DZ0.LSE
0DZ0.LSE

ChemoMetec and Roche Diagnostics sign collaboration agreement for bioprocess monitoring connectivity

ChemoMetec and Roche Diagnostics have entered a collaboration agreement to develop a connection kit linking the Roche Cedex® Bio Analyzer and the ChemoMetec Xcytomatic® 30 cell counting analyzer. The agreement follows a Letter of Intent signed in February 2026 and covers both development and subsequent commercialization of the connectivity solution. Roche will design the connection kit and handle verification and validation, aiming for seamless hardware and software integration between the two instruments. The companies will jointly promote the combined solution while each remains the sole seller of its own analyzers.
Yahoo Finance·16dRead more ▾